Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22054365 | 1.00 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL21037265 | 1.00 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL8163166 | 1.00 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL30641160 | 1.00 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL28982269 | 1.00 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL29963891 | 1.00 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL22066428 | 0.87 | DPP4 (0.46) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL8149597 | 0.87 | DPP4 (0.46) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL8158624 | 0.87 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A | |
| SCHEMBL21391324 | 0.87 | BRD4 (0.43) | BRD4L3MBTL1DPP4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134710-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2020-02-12 | — | — | EP | claimed |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3768271-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250388581-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-3898581-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12364694-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12331052-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-3768254-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-11407751-B2 | Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20190292185-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | BRD4 135/4885L3MBTL1 3634/4885DPP4 3556/4885 |
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | BRD4 1657/4885L3MBTL1 4510/4885DPP4 1289/4885 |
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | BRD4 155/4885L3MBTL1 3545/4885DPP4 3481/4885 |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | BRD4 155/4885L3MBTL1 3545/4885DPP4 3481/4885 |
| US-20190292185-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | BRD4 132/4885L3MBTL1 3566/4885DPP4 3492/4885 |
| US-20250388581-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | BRD4 2633/4885L3MBTL1 1834/4885DPP4 1962/4885 |
| US-12331052-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | BRD4 2499/4885L3MBTL1 3475/4885DPP4 2134/4885 |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | BRD4 155/4885L3MBTL1 3545/4885DPP4 3481/4885 |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | BRD4 155/4885L3MBTL1 3545/4885DPP4 3481/4885 |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | OPRK1, OPRM1, OPRD1 | BRD4 326/4885L3MBTL1 3074/4885DPP4 2990/4885 |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | BRD4 1657/4885L3MBTL1 4510/4885DPP4 1289/4885 |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | KCNH2, KCNH3, KCNH1 | BRD4 1070/4885L3MBTL1 3279/4885DPP4 4152/4885 |
| US-12364694-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | BRD4 2110/4885L3MBTL1 3356/4885DPP4 2027/4885 |
| US-11407751-B2 | Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline | COX5B, IDH3B, CYP2J2 | BRD4 1394/4885L3MBTL1 4796/4885DPP4 3755/4885 |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | CYP1B1, CYP4B1, CBR1 | BRD4 112/4885L3MBTL1 4398/4885DPP4 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.